(Alliance News) - Diurnal Group PLC said on Thursday its primary focus remains on progressing its two lead products, Chronocort and Alkindi.
The specialty pharmaceutical company said at its annual general meeting Chronocort and Alkindi are potentially valuable treatment options with a combined opportunity of over USD3.0 billion for diseases resulting from cortisol deficiency in the US and Europe.
The company remains on track to submit two key regulatory filings during the fourth quarter of 2019, a marketing authorisation application for Chronocort in Europe and a new drug application for Alkindi in the US.
Diurnal expects to conclude a licensing deal for its late-stage cortisol deficiency pipeline in the US in the first half of 2020.
Meanwhile, the commercial roll out of Alkindi in Europe continues to progress, with sales for the year to date in line with expectations, the company said.
Diurnal also said it continues to progress oral testosterone treatment DITEST, after a phase one proof-of-concept clinical trial delivered positive outcome.
Diurnal shares were 3.2% up in London at 32.00 pence each on Thursday.
By Loreta Juodagalvyte; loretajuodagalvyte@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
